Thermo Fisher Scientific (TMO)

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the research tools & consumables stocks, including Thermo Fisher (NYSE:TMO) and its peers.

Thermo Fisher Scientific stock may remain sluggish through November. What's behind the weakness and is TMO a buy now?

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.

Get insights into the top gainers and losers in the S&P500 index of Tuesday's pre-market session.

Regeneron (REGN) to acquire 23andMe for $256 million, plans to maintain consumer services and uphold privacy policies. Deal expected to close Q3 2025.

Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Wednesday as we examine the latest happenings in today's session.

Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states.

Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

Looking for the S&P500 stocks that are experiencing notable gaps on Wednesday? Find out which stocks are gapping up and gapping down in the S&P500 index during today's session.

A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides agreed to pause some tariffs for 90 days, signaling a potential turning point in ongoing tensions. This rollback cuts U.S. tariffs on Chinese goods to 30% and Chinese tariffs on U.S. imports to 10%, giving companies breathing room to reset inventories and supply chains. 

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.

FDA to increase surprise inspections at foreign facilities as U.S. companies pour billions into domestic drug and device manufacturing.

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".

Year to date, Thermo Fisher fell about 21.03%, both underperforming the iShares U.S. Healthcare ETF, which declined about 2.36%.

Life sciences company Revvity (NYSE:RVTY) will be reporting results tomorrow before market hours. Here’s what investors should know.

Thermo Fisher plans $2 billion U.S. investment amid tariff concerns, while analysts lower price targets despite reaffirming positive ratings.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 12.7%. This performance was worse than the S&P 500’s 7.5% fall.